Rheum to Breathe Banner
Dr. John Cush Tweet
@RheumNow
Worsening Breathlessness in SSc ILD Dr. Aurelie Najm, Glasgow, presents a QD Clinic on worsening breathlessness in systemic sclerosis interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/P3MoM7ZmIo
Article

Scleroderma-associated Interstitial Lung Disease

Marcy B. Bolster, MD

While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease

jpedrokessner Tweet
@KessnerJp
New Multidisciplinary Classification of the Interstitial Pneumonias: ATS/ERS Guideline. https://t.co/HWteOikGXT 🫁🩻🎞⚔️🐍🧪🔬💡📚 @ERSpublications @EuroRespSoc @ALATorax @SPLF_SocPneumo @pneumosbpt @NeumoMadrid @SeparRespira @HUReinaSofia @neumoparatodos @Neumosur @NeumoNat https://t.co/GnJjuxMIEm
Dr. John Cush Tweet
@RheumNow
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: 📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025 📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/BebFhDJ1mM
Dr. John Cush Tweet
@RheumNow
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD
Dr. John Cush Tweet
@RheumNow
Controversies in ILD This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj
Dr. John Cush Tweet
@RheumNow
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: 📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025 📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/l8EkX2hkLs
Dr. John Cush Tweet
@RheumNow
ILD and Mortality in Systemic Autoimmune Rheumatic Diseases Dr. Bryant England, Lincoln, NE, discusses interstitial lung disease and mortality in systemic autoimmune rheumatic diseases (SARDs), as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month https://t.co/wtg9Te6oth
Dr. John Cush Tweet
@RheumNow
SARD-ILD and serious infection risk: The elephant in the room Interstitial lung disease (ILD) remains one of the largest unmet clinical needs across many systemic autoimmune rheumatic diseases (SARD). ILD is highly prevalent across systemic sclerosis, mixed connective tissue https://t.co/oxIteGfUTd
Dr. John Cush Tweet
@RheumNow
QD Clinic: Application of the ACR CHEST Guidelines to Two Cases Dr. Sindhu Johnson, Toronto, discusses two cases that where the application of the ACR CHEST guidelines for the screening, monitoring and treatment of SSc-ILD and Rapidly Progressive ILD are applied, as part of https://t.co/ntW2WIvJ8c
Dr. John Cush Tweet
@RheumNow
Patient Resource: The Hidden Connection - ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/8rJm4O3hHU
Dr. John Cush Tweet
@RheumNow
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151 RA-ILD, 70 RA-BR). RA-LD higher mortality (34 vs 13/1000PY; HR
Dr. John Cush Tweet
@RheumNow
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/qRoTr3r84x
Dr. John Cush Tweet
@RheumNow
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by

Therapeutic Updates

ILD Treatment and Guidelines

Hinze title card
Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more.
Read Post

Campaign Videos

Podcasts

  • ILD Diagnosis, Screening and Monitoring
  • QD clinics on ILD - lessons from the Clinic #4
  • Rheum + Pulm Collaborations in ILD
×